Bjermer 2016.

Study characteristics
Methods	Parallel, double‐blind RCT with a 16‐week treatment phase
Participants	315 participants (42 male) with moderate‐severe asthma, with airway reversibility, blood eosinophilia, ACQ score of at least 1.5, and taking ICS Main inclusion/exclusion criteria: blood eosinophils ≥ 400 cells/μL during 2 to 4‐week screening period ACQ‐7 score ≥ 1.5 maintenance treatment with medium‐dose ICS (maintenance OCS not allowed) Mean age, years: reslizumab 0.3 mg/kg, 44.5; reslizumab 3 mg/kg, 43.0; placebo, 44.2 Male, n: reslizumab 0.3 mg/kg, 43; reslizumab 3 mg/kg, 42; placebo, 41 Baseline mean FEV1 % predicted: reslizumab 0.3 mg/kg, 69; reslizumab 3 mg/kg, 70; placebo, 71 Allocation, n: reslizumab 0.3 mg/kg, 104; reslizumab 3 mg/kg, 106; placebo, 105
Interventions	IV infusion of reslizumab 0.3 mg/kg, reslizumab 3.0 mg/kg, or placebo once every 4 weeks (total of 4 doses)
Outcomes	Primary outcome pre‐bronchodilator spirometry (FEV1) Secondary outcomes FVC, FEF 25%‐75% Asthma symptoms (ACQ, ACQ‐6, ACQ‐5), ASUI, AQLQ Rescue inhaler use Blood eosinophil levels
Notes	68 locations across 13 countries Funded by Teva Branded Pharmaceutical Products R&D, Inc
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated, no clarification available from study authors
Allocation concealment (selection bias)	Unclear risk	Not stated, no clarification available from study authors
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated, no clarification available from study authors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Slightly more withdrawals in placebo group (20/105, 19%) than treatment arms (12‐17%)
Selective reporting (reporting bias)	Low risk	All outcomes reported